BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+27.77%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$8.73B
AUM Growth
+$1.49B
(+21%)
Cap. Flow
+$238M
Cap. Flow
% of AUM
2.73%
Top 10 Holdings %
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
80
Reduced
68
Closed
12
Top Buys
| 1 |
Biogen
BIIB
|
$136M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$65.8M |
| 3 |
Mersana Therapeutics
MRSN
|
$51.3M |
| 4 |
Arvinas
ARVN
|
$46.7M |
| 5 |
AbbVie
ABBV
|
$36.3M |
Top Sells
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$154M |
| 2 |
Halozyme
HALO
|
$60.8M |
| 3 |
Pacific Biosciences
PACB
|
$57.2M |
| 4 |
CareDx
CDNA
|
$55.9M |
| 5 |
Charles River Laboratories
CRL
|
$52M |
Sector Composition
| 1 | Healthcare | 95.9% |
| 2 | Technology | 0.6% |
| 3 | Industrials | 0.33% |
| 4 | Financials | 0.11% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
GoHealth
GOCO
$78.2M
| $4.61M | 0.05% |
22,495
+1,517
| +7% | +$311K |
|
127
Zai Lab
ZLAB
$3.34B
| $4.43M | 0.05% |
32,700
-128,500
| -80% | -$17.4M |
|
128
Johnson & Johnson
JNJ
$431B
| $4.41M | 0.05% |
+28,000
| New | +$4.41M |
|
|
BNR
129
Burning Rock Biotech
BNR
$91M
| $4.28M | 0.05% |
18,529
+3,853
| +26% | +$890K |
|
130
Seer Inc
SEER
$114M
| $4.23M | 0.05% |
+75,336
| New | +$4.23M |
|
131
Labcorp
LH
$22.9B
| $3.87M | 0.04% |
22,154
-40,974
| -65% | -$7.16M |
|
132
Sarepta Therapeutics
SRPT
$1.93B
| $3.46M | 0.04% |
20,300
| – | – |
|
|
QTNT
133
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $3.43M | 0.04% |
16,434
-6,493
| -28% | -$1.35M |
|
134
Agilent Technologies
A
$36.4B
| $2.77M | 0.03% |
23,400
+17,200
| +277% | +$2.04M |
|
135
Apellis Pharmaceuticals
APLS
$3.62B
| $2.75M | 0.03% |
+48,000
| New | +$2.75M |
|
136
Pfizer
PFE
$140B
| $2.72M | 0.03% |
73,900
-3,991
| -5% | -$147K |
|
|
MRTX
137
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.7M | 0.03% |
12,300
-5,500
| -31% | -$1.21M |
|
|
ALLK
138
DELISTED
Allakos
ALLK
| $2.59M | 0.03% |
+18,500
| New | +$2.59M |
|
139
Coherus Oncology, Inc. Common Stock
CHRS
$152M
| $2.59M | 0.03% |
149,000
-1,254,400
| -89% | -$21.8M |
|
140
Ascendis Pharma
ASND
$12B
| $2.59M | 0.03% |
15,500
| – | – |
|
|
BMY.RT
141
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $2.5M | 0.03% |
3,617,446
+2,817,446
| +352% | +$1.94M |
|
|
GTH
142
DELISTED
Genetron Holdings Limited ADS
GTH
| $2.45M | 0.03% |
58,283
+4,813
| +9% | +$202K |
|
143
Acadia Pharmaceuticals
ACAD
$4.3B
| $2.4M | 0.03% |
44,900
| – | – |
|
|
CLLS
144
Cellectis
CLLS
$264M
| $2.26M | 0.03% |
83,500
| – | – |
|
145
FibroGen
FGEN
$45.7M
| $1.97M | 0.02% |
2,120
| – | – |
|
146
Kura Oncology
KURA
$706M
| $1.89M | 0.02% |
58,000
+10,000
| +21% | +$327K |
|
147
Revolution Medicines
RVMD
$7.28B
| $1.58M | 0.02% |
+40,000
| New | +$1.58M |
|
148
Xencor
XNCR
$597M
| $1.53M | 0.02% |
+35,100
| New | +$1.53M |
|
|
DRNA
149
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $1.5M | 0.02% |
+68,000
| New | +$1.5M |
|
150
BioNTech
BNTX
$24.9B
| $1.47M | 0.02% |
18,000
-31,500
| -64% | -$2.57M |
|